Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.2% – Here’s Why

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) dropped 4.2% on Monday . The company traded as low as $13.11 and last traded at $13.11. Approximately 40,547 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 232,004 shares. The stock had previously closed at $13.69.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SION. Guggenheim began coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price for the company. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price objective for the company. Finally, TD Cowen started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating on the stock.

Sionna Therapeutics Trading Down 16.1 %

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.